LYKA LABS
Quarterly Results Analysis [Dec2024]
LYKA LABS Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹34 Cr | ₹41 Cr | ₹30 Cr | ₹28 Cr | ₹33 Cr | ₹28 Cr | ₹23 Cr | ₹22 Cr |
Expenses | ₹29 Cr | ₹36 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹24 Cr | ₹20 Cr | ₹19 Cr |
Operating Income | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹7 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr |
Other Income | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr |
Depreciation | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr |
Profit Before Tax | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹-2 Cr | ₹3 Cr | ₹-1 Cr | ₹-2 Cr | ₹-3 Cr |
Profit After Tax | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹-2 Cr | ₹2 Cr | ₹-1 Cr | ₹-2 Cr | ₹-3 Cr |
EPS | ₹0.76 | ₹0.59 | ₹0.40 | ₹-0.64 | ₹0.54 | ₹-0.15 | ₹-0.56 | ₹-0.98 |
Industry Peers & Returns | 1W | 1M | 1Y |
LYKA LABS | 6.7% | 6.1% | -6.1% |
SUN PHARMACEUTICAL INDUSTRIES | 2.3% | 11.7% | 5.1% |
DIVIS LABORATORIES | -1.6% | 4% | 58.7% |
CIPLA | 0.8% | 6.2% | -2.9% |
TORRENT PHARMACEUTICALS | 0.7% | 9.8% | 19.8% |
DR REDDYS LABORATORIES | -1% | 2.8% | -8% |
MANKIND PHARMA | -1.4% | 4.5% | 4.7% |
ZYDUS LIFESCIENCES | 1.1% | 3.5% | -10.8% |
LUPIN | 3.7% | 7.3% | 23.8% |
LYKA LABS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -17.88 % |
Y-o-Y | 3.79 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹34 Cr | -17.88 | |
Sep2024 | ₹41 Cr | 36.66 | |
Jun2024 | ₹30 Cr | 8.45 | |
Mar2024 | ₹28 Cr | -14.73 | |
Dec2023 | ₹33 Cr | 16.36 | |
Sep2023 | ₹28 Cr | 22.33 | |
Jun2023 | ₹23 Cr | 2.87 | |
Mar2023 | ₹22 Cr | - |
LYKA LABS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 4.89 % |
Y-o-Y | -24.33 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹5 Cr | 4.89 | |
Sep2024 | ₹5 Cr | 33.59 | |
Jun2024 | ₹4 Cr | 82.70 | |
Mar2024 | ₹2 Cr | -70.44 | |
Dec2023 | ₹7 Cr | 64.25 | |
Sep2023 | ₹4 Cr | 58.06 | |
Jun2023 | ₹3 Cr | -19.78 | |
Mar2023 | ₹3 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 27.76 % |
Y-o-Y | -27.09 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 15.37% | 27.76 | |
Sep2024 | 12.03% | -2.27 | |
Jun2024 | 12.31% | 68.40 | |
Mar2024 | 7.31% | -65.32 | |
Dec2023 | 21.08% | 41.19 | |
Sep2023 | 14.93% | 29.15 | |
Jun2023 | 11.56% | -22.00 | |
Mar2023 | 14.82% | - |
LYKA LABS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 41.47 % |
Y-o-Y | 34.31 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹3 Cr | 41.47 | |
Sep2024 | ₹2 Cr | 48.33 | |
Jun2024 | ₹1 Cr | Positive | |
Mar2024 | ₹-2 Cr | Negative | |
Dec2023 | ₹2 Cr | Positive | |
Sep2023 | ₹-1 Cr | Negative | |
Jun2023 | ₹-2 Cr | Negative | |
Mar2023 | ₹-3 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 72.04 % |
Y-o-Y | 29.45 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 8 % | 72.04 | |
Sep2024 | 4.65 % | 8.64 | |
Jun2024 | 4.28 % | Positive | |
Mar2024 | -7.52 % | Negative | |
Dec2023 | 6.18 % | Positive | |
Sep2023 | -2.2 % | Negative | |
Jun2023 | -8.44 % | Negative | |
Mar2023 | -13.47 % | - |
LYKA LABS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 28.81 % |
Y-o-Y | 40.74 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹0.76 | 28.81 | |
Sep2024 | ₹0.59 | 47.50 | |
Jun2024 | ₹0.4 | Positive | |
Mar2024 | ₹-0.64 | Negative | |
Dec2023 | ₹0.54 | Positive | |
Sep2023 | ₹-0.15 | Negative | |
Jun2023 | ₹-0.56 | Negative | |
Mar2023 | ₹-0.98 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD